-+ 0.00%
-+ 0.00%
-+ 0.00%

Gain Therapeutics To Give Oral Presentation Update On GCase Modulator For Parkinson's Disease At 3rd International GBAI Meeting May 22-23

Benzinga·04/24/2026 12:33:19
Listen to the news

Gain Therapeutics' lead drug candidate, GT-02287, is in clinical development for the treatment of Parkinson's disease (PD) with or without a GBA1 mutation. The orally administered, brain-penetrant small molecule is an allosteric enzyme modulator that restores the function of the lysosomal enzyme glucocerebrosidase (GCase) which becomes misfolded and impaired due to mutations in the GBA1 gene, the most common genetic abnormality associated with PD, or other age-related stress factors.